Celecoxib/Metformin/Valsartan - ARKAY Therapeutics

Drug Profile

Celecoxib/Metformin/Valsartan - ARKAY Therapeutics

Alternative Names: RK-01

Latest Information Update: 07 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ARKAY Therapeutics
  • Class Anti-inflammatories; Antihyperglycaemics; Biguanides; Branched-chain amino acids; Non-opioid analgesics; Nonsteroidal anti-inflammatories; Pyrazoles; Small molecules; Sulfonamides; Tetrazoles
  • Mechanism of Action AMP activated protein kinase stimulants; Angiotensin type 1 receptor antagonists; Cyclo-oxygenase 2 inhibitors; Gluconeogenesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Type 2 diabetes mellitus

Most Recent Events

  • 24 Apr 2018 Chemical structure information added
  • 11 Apr 2018 Arkay Therapeutics files an IND application with the USFDA for Human Proof-of-Concept (PoC) Trial in Type-2 diabetes mellitus
  • 29 Mar 2018 Preclinical trials in Type-2 diabetes mellitus in USA (PO) (before March 2018) (ARKAY Therapeutics pipeline)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top